Fixed topical combinations in glaucomatous patients and ocular discomfort

Bibliography

• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7
   PubMed Web of Science ®Google Scholar
• Gordon MO, Beiser JA, Brandt JD, The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20; discussion 829-830
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hussein M, Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48-56
   PubMed Web of Science ®Google Scholar
• Bengtsson B, Heijl A. A long term prospective study of risk factors for glaucomatous visual field loss in patients with ocular hypertension. J Glaucoma 2005;14:135-8
   PubMed Web of Science ®Google Scholar
• Maier PC, Funk J, Schwarzer G, Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 2005;331:134-6
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hyman L, Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007;114:1965-72
   PubMed Web of Science ®Google Scholar
• No authors listed. The Advanced Glaucoma Intervention Study (AGIS): The relationship between control of intraocular pressure and visual field deterioration. The AGIS investigators. Am J Ophthalmol 2000;130:429-40
   PubMedGoogle Scholar
• Kass MA, Heuer DK, Higginbotham EJ, The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• Tsai JC, McClure CA, Ramos SE, Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003;12:393-8
   PubMed Web of Science ®Google Scholar
• Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005;112:863-8
   PubMed Web of Science ®Google Scholar
• Robin AL, Novack GD, Covert DW, Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007;144:533-40
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004;15:132-5
   PubMedGoogle Scholar
• Noecker RJ. The management of glaucoma and intraocular hypertension: current approaches and recent advances. Ther Clin Risk Manag 2006;2:193-206
   PubMedGoogle Scholar
• Dunn FG, Frohlich ED. Pharmacokinetics, mechanisms of action, indications, and adverse effects of timolol maleate, a nonselective beta-adrenoreceptor blocking agent. Pharmacotherapy 1981;1:188-200
   PubMed Web of Science ®Google Scholar
• Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol 2000;44(Suppl 2):S141-5
   PubMedGoogle Scholar
• Sanchez-Pulgarin M, Martinez-de-la-Casa JM, Garcia-Feijoo J, Comparative study of the pressure lowering efficacy and variations in the ocular pulse amplitude between fixed combinations of dorzolamide/timolol and brinzolamide/timolol. Arch Soc Esp Oftalmol 2011;86:149-53
   PubMedGoogle Scholar
• Nebbioso M, De Gregorio F, Prencipe L, Psychophysical and Electrophysiological Testing in Ocular Hypertension. Optom Vis Sci 2011;88:E928-39
   PubMed Web of Science ®Google Scholar
• Schiffman RM, Christianson MD, Gordon J, Reliability and validity of the ocular surface disease index. Arch ophthalmol 2000;118:615-21
   PubMed Web of Science ®Google Scholar
• Bell NP, Ramos JL, Feldman RM. Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension. Clin Ophthalmol 2010;4:1331-46
   PubMedGoogle Scholar
• Baudouin C, Pisella PJ, Fillacier K, Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. REFJ 1999;106:556-63
   Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002;86:418-23
   PubMed Web of Science ®Google Scholar
• Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Rev Ophthalmol 2009;4:59-64
   Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350-5
   PubMed Web of Science ®Google Scholar
• De Saint Jean M, Brignole F, Bringuier AF, Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999;40:619-30
   PubMed Web of Science ®Google Scholar
• Dogan AS, Orhan M, Soylemezoglu F, Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients. Clin Experiment Ophthalmol 2004;32:62-6
   PubMed Web of Science ®Google Scholar
• Vaede D, Baudouin C, Warnet JM, Preservatives in eye drops: towards awareness of their toxicity. J Fr Ophtalmol 2010;33:505-24
   PubMed Web of Science ®Google Scholar
• Green K, Tonjum A. Influence of various agents on corneal permeability. Am J Ophthalmol 1971;72:897-905
   PubMed Web of Science ®Google Scholar
• Baudouin C, Liang H, Hamard P, The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology 2008;115:109-15
   PubMed Web of Science ®Google Scholar
• Pauly A, Meloni M, Brignole-Baudouin F, Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest Ophthalmol Vis Sci 2009;50:1644-52
   PubMed Web of Science ®Google Scholar
• Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004;23:490-6
   PubMed Web of Science ®Google Scholar
• Blondin C, Hamard P, Cholley B, In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system. Curr Eye Res 2003;27:253-9
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Debbasch C, Hamard P, Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004;45:1360-8
   PubMed Web of Science ®Google Scholar
• Martone G, Frezzotti P, Tosi GM, An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol 2009;147:725-35; e1
   PubMed Web of Science ®Google Scholar
• Ammar DA, Kahook MY. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis 2011;17:1806-13
   PubMed Web of Science ®Google Scholar
• Bensoussan L, Blondin C, Baudouin C, Flow cytometric analysis of HLA-DR. IL-6 and IL-8 expression by conjunctival epithelial cells from patients with prolonged topical antiglaucoma treatments. J Fr Ophtalmol 2003;26:782-9
   PubMed Web of Science ®Google Scholar
• Beckers HJ, Schouten JS, Webers CA. Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension. Clin Ophthalmol 2009;3:593-9
   PubMedGoogle Scholar
• Mundorf TK, Rauchman SH, Williams RD, A patient preference comparison of Azarga (brinzolamide/timolol fixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2008;2:623-8
   PubMedGoogle Scholar
• Barnebey H, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 2000;22:1204-12
   PubMed Web of Science ®Google Scholar
• Stewart WC, Day DG, Stewart JA, Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs. placebo in primary open-angle glaucoma and ocular hypertension subjects. Eye 2004;18:905-10
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Sandolo F, From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study. Expert Opin Pharmacother 2011;12:2425-31
   PubMed Web of Science ®Google Scholar
• Tsukamoto H, Noma H, Mukai S, The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide. J Ocul Pharmacol Ther 2005;21:395-9
   PubMed Web of Science ®Google Scholar